Delivery Order SPE2DB22D1200-SPE2DB25FN2AJ

Award Date 5/19/25
Potential Completion Date 5/20/25
Potential Value $1.9K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a Delivery Order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of OLOPATADINE HCL 0.1% EYE DROPS 5ML. The contract has a ceiling value of $2,887.30 and a completion date of January 8, 2025. It is a Firm Fixed Price contract with no set-aside designation, indicating open competition. AmerisourceBergen holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA). The contract, valued at $1,308.39, is for the delivery of OLOPATADINE HCL 0.1% eye drops in 5ml quantities. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as the primary vehicle for...
This is a Delivery Order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Olopatadine HCl 0.1% eye drops. The contract has a ceiling value of $3,580.00 and a period of performance through April 2025. It is a Firm Fixed Price contract, without any set-aside designation, indicating open competition. AmerisourceBergen Drug Corp holds a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of Olopatadine Hydrochloride 0.1% eye drops. The $2,112.82 firm-fixed-price contract has a performance period through May 2025 and is not set aside. Amerisourcebergen holds a larger $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, which provides a comprehensive global pharmaceutical support vehicle through...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $1,978.46, is for the supply of Olopatadine HCl 0.1% eye drops, a pharmaceutical product used for the treatment of eye conditions. The contract has an ultimate completion date of April 7, 2025. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA), a defense agency, to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Olopatadine HCl 0.1% eye drops. The contract has a ceiling value of $1,034.90 and a completion date of June 24, 2025. It is not a set-aside contract, indicating open competition. AmerisourceBergen Drug Corp also holds a $999,999,999.00 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Olopatadine HCl 0.1% eye drops, a pharmaceutical product, with a ceiling value of $1,058.20 and a completion date of March 28, 2025. The contract is a Firm Fixed Price Delivery Order, with no set-aside designation indicated. AmerisourceBergen holds a significant Indefinite Delivery...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp for the supply of OLOPATADINE HCL 0.1% EYE DROPS 5ML. The contract has a firm fixed price of $4,249.70 and a period of performance through June 11, 2024. This award is associated with a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC serves as...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of Olopatadine Hydrochloride 0.1% Eye Drops, 5 milliliter, and has a ceiling value of $1,701.55. The contract is not set aside and was awarded on May 12, 2025, with a final completion date of May 13, 2025. Amerisourcebergen Drug Corp is a for-profit organization that...
This is a federal contract award issued by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of Olopatadine HCl 0.1% eye drops in 5 ml vials, with a total ceiling value of $1,696.92 and a completion date of January 27, 2025. The contract is a firm fixed-price Delivery Order and does not have a set-aside designation, indicating open competition....
  • SPE2DB22D1200
    Indefinite Delivery Contract
  • SPE2DB22D1200-SPE2DB25FN2AJ
    Delivery Order

This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of OLOPATADINE HCL 0.1% EYE DROPS 5ML, with a ceiling value of $1,883.30 and a firm fixed price. The contract has an ultimate completion date of May 20, 2025.

Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00 and designated as SPE2DX. This prime contract provides a comprehensive global pharmaceutical support vehicle with a performance period extending through December 2026, enabling the company to supply a vast range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, serving customers including the Defense Health Agency and U.S. Coast Guard. The contract award is not set-aside, indicating open competition.

Generated 8/18/25, 9:45 AM